Humacyte Non Current Liabilities Other from 2010 to 2025

HUMAW Stock  USD 1.00  0.09  8.26%   
Humacyte Non Current Liabilities Other yearly trend continues to be fairly stable with very little volatility. Non Current Liabilities Other is likely to outpace its year average in 2025. During the period from 2010 to 2025, Humacyte Non Current Liabilities Other regression line of quarterly data had mean square error of 480 T and geometric mean of  14,005,983. View All Fundamentals
 
Non Current Liabilities Other  
First Reported
2010-12-31
Previous Quarter
44.5 M
Current Value
49.5 M
Quarterly Volatility
26.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Humacyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Humacyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.7 M, Interest Expense of 1.2 M or Selling General Administrative of 21.1 M, as well as many indicators such as Price To Sales Ratio of 96.95, Dividend Yield of 0.0 or PTB Ratio of 20.49. Humacyte financial statements analysis is a perfect complement when working with Humacyte Valuation or Volatility modules.
  
Check out the analysis of Humacyte Correlation against competitors.
For more information on how to buy Humacyte Stock please use our How to Invest in Humacyte guide.

Latest Humacyte's Non Current Liabilities Other Growth Pattern

Below is the plot of the Non Current Liabilities Other of Humacyte over the last few years. It is Humacyte's Non Current Liabilities Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Humacyte's overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Other10 Years Trend
Slightly volatile
   Non Current Liabilities Other   
10428.38.44.49.-73%35%15%11%100%
       Timeline  

Humacyte Non Current Liabilities Other Regression Statistics

Arithmetic Mean22,136,213
Geometric Mean14,005,983
Coefficient Of Variation120.13
Mean Deviation19,439,893
Median7,998,109
Standard Deviation26,591,326
Sample Variance707.1T
Range96.8M
R-Value0.61
Mean Square Error480T
R-Squared0.37
Significance0.01
Slope3,380,770
Total Sum of Squares10606.5T

Humacyte Non Current Liabilities Other History

202549.5 M
202444.5 M
202338.7 M
202228.6 M
2021104.8 M

About Humacyte Financial Statements

Humacyte investors use historical fundamental indicators, such as Humacyte's Non Current Liabilities Other, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Humacyte. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Current Liabilities Other44.5 M49.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Humacyte Stock Analysis

When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.

Discover investing ideas

Utilize additional investing modules

News Freq…Investor S…